Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations

被引:34
|
作者
Shen, Jie [1 ]
Lu, Guang Wei [2 ]
Hughes, Patrick [3 ]
机构
[1] Allergan Plc, Clin Pharmacol Nonclin & Translat Sci, 2525 Dupont Dr, Irvine, CA 92612 USA
[2] TWi Pharmaceut Inc, Ophthalm Prod Dev, Taipei, Taiwan
[3] Glaukos Corp, Appl Res, San Clemente, CA USA
关键词
formulation; ocular; pharmacokinetic; pharmacodynamic; sustained release; targeted delivery; EPISCLERAL CYCLOSPORINE IMPLANT; IN-VITRO; SUBCONJUNCTIVAL BEVACIZUMAB; SUSTAINED-RELEASE; VIVO EVALUATION; AQUEOUS-HUMOR; GLAUCOMA; PHARMACOKINETICS; LATANOPROST; ABSORPTION;
D O I
10.1007/s11095-018-2498-y
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The development of ophthalmic drug delivery systems is a long and comprehensive process including research, nonclinical, and clinical development stages. It is critical to understand the similarity and differences between animal models and patients. There are many anatomically and physiologically important parameters for targeted drug delivery into eyes. This paper reviews the constraints to various routes of ocular drug delivery and discusses the respective pharmacokinetic considerations, to lay the foundation for formulation approaches pharmaceutical scientists can use to maximize successful drug delivery for each route. The overall goal is to give both researchers and drug developers a better understanding of ocular drug delivery and offer tools to successfully develop new medicines that will fulfil unmet medical needs and improve patients' quality of life.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Use of opioids in the elderly - Pharmacokinetic and pharmacodynamic considerations
    Freye, E
    Levy, JV
    ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2004, 39 (09): : 527 - 537
  • [42] Pharmacokinetic and pharmacodynamic considerations of cephalosporin use in children
    Tauzin, Manon
    Ouldali, Naim
    Bechet, Stephane
    Caeymaex, Laurence
    Cohen, Robert
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (11) : 869 - 880
  • [43] Pharmacokinetic/pharmacodynamic considerations for epilepsy - depression comorbidities
    Banach, Monika
    Poplawska, Monika
    Blaszczyk, Barbara
    Borowicz, Kinga K.
    Czuczwar, Stanislaw J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1067 - 1080
  • [44] Ocular pharmacokinetic/pharmacodynamic modeling for timolol in rabbits using a telemetry system
    Sakanaka, Koji
    Kawazu, Kouichi
    Tomonari, Masahide
    Kitahara, Takashi
    Nakashima, Mikiro
    Nishida, Koyo
    Nakamura, Junzo
    Sasaki, Hitoshi
    Higuchi, Shun
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (05) : 970 - 975
  • [45] Physics considerations in targeted anticancer drug delivery by magnetoelectric nanoparticles
    Stimphil, Emmanuel
    Nagesetti, Abhignyan
    Guduru, Rakesh
    Stewart, Tiffanie
    Rodzinski, Alexandra
    Liang, Ping
    Khizroev, Sakhrat
    APPLIED PHYSICS REVIEWS, 2017, 4 (02):
  • [46] Cubosomes: Design, Development, and Tumor-Targeted Drug Delivery Applications
    Umar, Hassaan
    Wahab, Habibah A.
    Gazzali, Amirah Mohd
    Tahir, Hafsa
    Ahmad, Waqas
    POLYMERS, 2022, 14 (15)
  • [47] Lipid Nanocarrier: an Efficient Approach Towards Ocular Delivery of Hydrophilic Drug (Valacyclovir)
    Kumar, Rakesh
    Sinha, V. R.
    AAPS PHARMSCITECH, 2017, 18 (03): : 884 - 894
  • [48] Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems
    Gupta, Bharti
    Mishra, Varsha
    Gharat, Sankalp
    Momin, Munira
    Omri, Abdelwahab
    PHARMACEUTICALS, 2021, 14 (11)
  • [49] Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures
    de Biase, Stefano
    Gigli, Gian Luigi
    Nilo, Annacarmen
    Romano, Giorgia
    Valente, Mariarosaria
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (02) : 93 - 102
  • [50] Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery
    Duxfield, Linda
    Sultana, Rubab
    Wang, Ruokai
    Englebretsen, Vanessa
    Deo, Samantha
    Swift, Simon
    Rupenthal, Ilva
    Al-Kassas, Raida
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2016, 21 (02) : 172 - 179